Mediolanum International Funds Ltd Acquires Shares of 124,624 Indivior PLC (NASDAQ:INDV)

Mediolanum International Funds Ltd acquired a new stake in Indivior PLC (NASDAQ:INDV) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 124,624 shares of the company’s stock, valued at approximately $1,240,000.

Other institutional investors also recently bought and sold shares of the company. M&G Plc acquired a new stake in Indivior in the first quarter valued at approximately $2,518,000. Janus Henderson Group PLC grew its holdings in Indivior by 14.2% in the first quarter. Janus Henderson Group PLC now owns 440,121 shares of the company’s stock valued at $9,424,000 after purchasing an additional 54,750 shares during the period. Vanguard Group Inc. grew its holdings in Indivior by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock valued at $90,081,000 after purchasing an additional 52,836 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Indivior in the first quarter worth approximately $1,523,000. Finally, Susquehanna International Group Ltd. acquired a new stake in shares of Indivior in the second quarter worth approximately $3,224,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

INDV has been the topic of a number of research analyst reports. Craig Hallum lowered their price target on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, October 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price target (up from $15.00) on shares of Indivior in a research note on Friday.

Indivior Stock Performance

Shares of NASDAQ:INDV opened at $9.00 on Monday. Indivior PLC has a 1 year low of $7.33 and a 1 year high of $23.22. The firm has a market capitalization of $1.24 billion, a PE ratio of 900.00 and a beta of 0.68. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68. The business’s 50 day moving average price is $10.13 and its 200-day moving average price is $13.76.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. The firm had revenue of $307.00 million for the quarter, compared to the consensus estimate of $302.25 million. As a group, equities research analysts expect that Indivior PLC will post 1.6 earnings per share for the current fiscal year.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.